# Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

> **NCT05758415** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 60 (actual)

## Conditions studied

- Rotator Cuff Tendinopathy

## Interventions

- **DRUG:** Secukinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05758415
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-02
- **Primary completion:** 2024-10-17
- **Final completion:** 2024-12-11
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** Project discontinued to prioritize other key programs in portfolio
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05758415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05758415, "Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05758415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*